According to the agreement, Hanson Pharmaceuticals grants Merck the exclusive global license to develop, produce, and commercialize HS-10535. Hansen Pharmaceuticals will receive a down payment of $112 million and is eligible for milestone payments of up to $1.9 billion based on the development, registration approval, and commercialization progress of candidate drugs. Under specific conditions, Hanson Pharmaceuticals may jointly promote or exclusively commercialize HS-10535 in China.
Ms. Sun Yuan, Executive Director of the Board of Directors of Hanson Pharmaceuticals, said, "We are pleased to announce the licensing agreement for HS-10535 with Merck. We believe that Merck's professional capabilities are crucial for accelerating the development of this promising asset and benefiting patients worldwide.
Dr. Li Yaodi, President of Merck Laboratories, said, "We continue to enhance and supplement our strong product pipeline through science driven business expansion. Through this agreement, we will evaluate the potential of HS-10535 based on our research experience in intestinal insulinotropic biology, including its potential to provide additional cardiac metabolic benefits beyond weight loss.
<Reprinted from WuXi AppTec>
